{"organizations": [], "uuid": "5296bb235bbe223acfb2207e7713177d4dd78b2a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-teva-presents-new-long-term-data-d/brief-teva-presents-new-long-term-data-demonstrating-efficacy-safety-of-copaxone-40-mg-ml-idUSFWN1S41V9", "country": "US", "domain_rank": 408, "title": "BRIEF-Teva Presents New Long-Term Data Demonstrating Efficacy & Safety Of Copaxone 40 Mg/Ml", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-27T22:52:00.000+03:00", "replies_count": 0, "uuid": "5296bb235bbe223acfb2207e7713177d4dd78b2a"}, "author": "", "url": "https://www.reuters.com/article/brief-teva-presents-new-long-term-data-d/brief-teva-presents-new-long-term-data-demonstrating-efficacy-safety-of-copaxone-40-mg-ml-idUSFWN1S41V9", "ord_in_thread": 0, "title": "BRIEF-Teva Presents New Long-Term Data Demonstrating Efficacy & Safety Of Copaxone 40 Mg/Ml", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "efficacy & safety of copaxone", "sentiment": "none"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "teva", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "teva pharmaceutical industries ltd", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 27, 2018 / 7:52 PM / Updated 25 minutes ago BRIEF-Teva Presents New Long-Term Data Demonstrating Efficacy & Safety Of Copaxone 40 Mg/Ml Reuters Staff 1 Min Read\nApril 28 (Reuters) - Teva Pharmaceutical Industries Ltd :\n* TEVA PRESENTS NEW LONG-TERM DATA DEMONSTRATING EFFICACY AND SAFETY OF COPAXONE (GLATIRAMER ACETATE INJECTION) 40 MG/ML\n* TEVA PHARMACEUTICAL INDUSTRIES LTD - NO NEW OR UNEXPECTED ADVERSE EVENTS EMERGED IN PATIENTS RECEIVING COPAXONE 40 MG/ML FOR UP TO 7 YEARS\n* TEVA PHARMACEUTICAL INDUSTRIES LTD - ADVERSE EVENTS WERE GENERALLY MILD AND CONSISTENT WITH WELL-ESTABLISHED SAFETY PROFILE OF COPAXONE Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-27T22:52:00.000+03:00", "crawled": "2018-04-27T23:18:20.014+03:00", "highlightTitle": ""}